PEGYLATED OPIOIDS WITH LOW POTENTIAL FOR ABUSE AND SIDE EFFECTS
Provided are methods for reducing the addiction potential and/or reducing one or more CNS-side effects related to the administration of an opioid analgesic drug by administering the opioid analgesic drug in the form of an oligomeric polyethylene glycol conjugate compound. The compounds provided demonstrate notably reduced potential for substance abuse, and possess altered pharmacokinetic profiles relative to the opioid agonists alone, but are not subject to the risk of physical tampering that allows for the recovery and abuse of the opioid agonist associated with certain alternative delivery formulations.
1 . A method for reducing the addiction potential and reducing one or more central nervous system (CNS) side-effects related to administration of an opioid analgesic drug (OP), the method comprising:
administering to a mammalian subject suffering from pain a therapeutically effective amount of an opioid compound having the formula:
OP—X—(CH 2 CH 2 O) n Y,
or a pharmaceutically acceptable salt form thereof,
wherein OP is an opioid analgesic drug, X is a physiologically stable linker, n is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, and Y is selected from a capping group, H, and a protecting group, whereby as a result of the administering, a degree of pain relief is experienced by the subject, and when evaluated in a suitable animal model, the opioid compound exhibits (i) a measurable reduction in addiction potential over the opioid analgesic drug in unconjugated form, and (ii) a ten-fold or greater reduction of at least one CNS-related side effect when compared to administration of the opioid analgesic drug in unconjugated form.
2 . A method for reducing one or more central-nervous system side-effects related to administration of an opioid analgesic drug (OP) by administering the opioid analgesic drug to a mammalian subject in the following form:
OP—X—(CH 2 CH 2 O) n Y
wherein OP is an opioid analgesic drug, X is a physiologically stable linker, n is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, and Y is selected from a capping group, H, and a protecting group.
3 . Use of an opioid compound having the formula:
OP—X—(CH 2 CH 2 O) n Y,
wherein OP is an opioid analgesic drug, X is a physiologically stable linker, n is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, and Y is selected from a capping group, H, and a protecting group, for simultaneously reducing the addiction potential and one or more central nervous system (CNS) side-effects related to administration of the opioid analgesic drug (OP) in unconjugated form.
4 . The use of an opioid compound having the formula:
OP—X—(CH 2 CH 2 O) n Y,
wherein OP is an opioid analgesic drug, X is a physiologically stable linker, n is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, and Y is selected from a capping group, H, and a protecting group, for the manufacture of a medicament for reducing the addiction potential and reducing one or more central nervous system (CNS) side-effects related to administration of an opioid analgesic drug (OP).
5 . The method of claim 1 , wherein the opioid analgesic drug is a mu-opioid analgesic.
6 . The method of claim 1 , wherein the opioid analgesic drug is selected from fentanyl, nalbuphine, hydromorphone, methadone, morphine, codeine, oxycodone, and oxymorphone.
7 . The method of claim 6 , wherein X is oxygen.
8 . The method of claim 7 , wherein the opioid compound has a structure selected from:
9 . The method of claim 8 , wherein the opioid compound has the structure:
10 . The method of claim 1 , wherein the administering comprises orally administering the opioid compound.
11 . The method of claim 1 , wherein the administering comprises parenterally administering the opioid compound.
12 . The method of claim 1 , wherein the opioid compound exhibits a measurable reduction in addiction potential over the opioid analgesic drug in unconjugated form when evaluated in an in-vivo self-administration model in rodents or primates.
13 . The method of claim 1 , wherein the opioid compound exhibits a ten-fold or greater reduction in at least one CNS-related side effect associated with administration of the opioid analgesic drug in unconjugated form when evaluated in a mouse model, wherein the one or more CNS-related side effects is selected from straub tail response, locomotor ataxia, tremor, hyperactivity, hypoactivity, convulsions, hindlimb splay, muscle rigidity, pinna reflex, righting reflex and placing.
14 . The method of claim 13 , wherein the opioid compound exhibits a ten-fold or greater reduction in at least one CNS-related side effect associated with administration of the opioid analgesic drug in unconjugated form when evaluated in a mouse model, wherein the one or more CNS-related side effects is selected from straub tail response, muscle rigidity, and pinna reflex.
15 . The method of claim 1 , effective to reduce one or more central nervous system side-effects associated with administration of the opioid analgesic drug in unconjugated form in a mammalian subject selected from respiratory depression, sedation, myoclonus, and delirium.
16 . The method of claim 1 , wherein the amount of opioid compound provided results in both an analgesic effect and a reduction of one or more central nervous system side effects associated with administration of the opioid analgesic drug in unconjugated form in a mammalian subject.
17 . The method of claim 1 further comprising monitoring the patient over the course of treatment for abuse/addiction potential and/or the existence of one or more CNS-side effects associated with administration of the opioid analgesic.
18 . The method of claim 17 , wherein, in the event abuse/addiction potential and/or the existence of one or more CNS-side effects is observed, the monitoring further comprises an assessment of the degree of such abuse/addiction potential and/or CNS-side effect.